China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.63
21.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one China Resources Double-Crane Pharmaceutical Co Ltd stock under the Base Case scenario is 21.81 CNY. Compared to the current market price of 18.94 CNY, China Resources Double-Crane Pharmaceutical Co Ltd is Undervalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
China Resources Double-Crane Pharmaceutical Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
C
|
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
|
19.7B CNY | 1.8 | 12.5 | 11 | 11 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
972.2B USD | 16.3 | 52.8 | 35.4 | 38 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.5B USD | 5.8 | 20.4 | 14.3 | 17.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF | 4.4 | 29 | 12.4 | 14.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP | 4.9 | 30.2 | 19.7 | 28.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF | 5 | 19.3 | 15.5 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.1B USD | 4.2 | 14.3 | 10.1 | 12 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK | 5.2 | 15.9 | 11.1 | 12.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD | 2.4 | 15.1 | 7.6 | 10.4 | |
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR | 1.4 | 6.8 | 6.2 | 6.2 |
